公开(公告)号：US20240216369A1

公开(公告)日：2024-07-04

申请号：US17755435

申请日：2020-10-30

Applicant: Novartis AG

Inventor： Martin BEIBEL ,  Beth BOROWSKY ,  Jang-Ho CHA ,  Thomas FALLER ,  Baltazar GOMEZ-MANCILLA ,  Caroline GUBSER KELLER ,  Marc LAISNEY ,  Wen LIN ,  Nicole RENAUD ,  Rajeev SIVASANKRAN

IPC: A61K31/501 ,  A61K9/00 ,  A61K9/08 ,  A61K45/06 ,  A61K47/40 ,  A61P25/28

CPC classification number: A61K31/501 ,  A61K9/0053 ,  A61K9/08 ,  A61K45/06 ,  A61K47/40 ,  A61P25/28

Abstract: Use of a splicing modulator for a treatment slowing progression of Huntington's disease.

公开(公告)号：US20230293529A1

公开(公告)日：2023-09-21

申请号：US17999694

申请日：2021-05-25

Applicant: Novartis AG

Inventor： Yi GU ,  Sebastien JEAY ,  Yi JIN ,  Marc LAISNEY ,  Christophe MEILLE ,  Prakash Dahyabhai MISTRY ,  Jonathan Guy MOGGS ,  Andreas WEISS ,  Mélanie Monique Laura WILBAUX

IPC: A61K31/519 ,  A61P35/00

CPC classification number: A61K31/519 ,  A61P35/00

Abstract: The invention provided herein provides dosage and dosage regimens for N-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine (Compound (1)), or a pharmaceutically acceptable salt thereof, Compound (1) for the treatment of PRC2-mediated diseases or disorders. In addition, the invention provides using such dosage and dosage regimens in methods for treating PRC2-mediated diseases or disorders.